Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.87
-0.32 (-2.90%)
May 26, 2026, 2:00 PM EDT - Market open

Keros Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
33.18244.063.550.15-20.1
Revenue Growth (YoY)
-84.55%6774.96%2250.99%---
Gross Profit
33.18244.063.550.15-20.1
Selling, General & Admin
46.546.8540.7534.8327.5321.33
Research & Development
97.03129.64173.63135.2687.2755.14
Total Operating Expenses
143.53176.49214.38170.09114.7976.47
Operating Income
-110.3567.57-210.83-169.94-114.79-56.37
Interest Income
20.4124.8723.514.763.640.03
Interest Expense
-----0-0
Other Non-Operating Income (Expense)
-0.37-0.540.282.196.47-0.38
Total Non-Operating Income (Expense)
20.0424.3323.7816.9510.11-0.36
Pretax Income
-90.3191.9-187.05-152.99-104.68-56.73
Provision for Income Taxes
5.16-4.88-0.3---2.01
Net Income
-85.1587.01-187.35-152.99-104.68-58.74
Net Income to Common
-85.1587.01-187.35-152.99-104.68-58.74
Shares Outstanding (Basic)
323737292523
Shares Outstanding (Diluted)
323837292523
Shares Change (YoY)
-17.41%1.13%27.13%16.66%8.17%50.48%
EPS (Basic)
-3.012.34-5.00-5.20-4.15-2.52
EPS (Diluted)
-3.012.30-5.00-5.20-4.15-2.52
Shares Outstanding
19.7319.5440.5531.8427.5423.97
Free Cash Flow
-58.25105.95-162.8-126.97-71.3-63.17
Free Cash Flow Per Share
-1.822.80-4.35-4.31-2.82-2.71
Gross Margin
100.00%100.00%100.00%100.00%-100.00%
Operating Margin
-332.55%27.69%-5938.96%-112544.00%--280.46%
Profit Margin
-256.60%35.65%-5277.55%-101319.00%--292.26%
FCF Margin
-175.56%43.41%-4585.92%-84087.40%--314.29%
EBITDA
-108.7869.08-209.6-169.13-114.12-56
EBITDA Margin
-327.83%28.30%-5904.34%-112004.00%--278.58%
EBIT
-110.3567.57-210.83-169.94-114.79-56.37
EBIT Margin
-332.55%27.69%-5938.96%-112544.00%--280.46%
Effective Tax Rate
-5.71%-5.31%0.16%0.00%0.00%3.54%
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q